FDA inspectors occasionally show lack of "respect," not "retaliation," FDAer tells conference.
FDA INSPECTION PROGRAM "CULTURE PROBLEMS" DO NOT INCLUDE "RETALIATION," FDA Midwest Region Director Burton Love told a PDA/ FDA joint conference on regulatory compliance in Bethesda, Md. Sept. 20. FDA's Office of Regulatory Affairs has been examining the issue of alleged retaliation by FDA inspectors, Love said. While the agency may have "culture problems," he said, "my observation is that we...probably don't have what is called `retaliation.'" However, "we occasionally have people that don't treat other people with respect."
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth